158 related articles for article (PubMed ID: 19712767)
1. The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali.
Traore B; Koné Y; Doumbo S; Doumtabé D; Traoré A; Crompton PD; Mircetic M; Huang CY; Kayentao K; Dicko A; Sagara I; Ellis RD; Miura K; Guindo A; Miller LH; Doumbo OK; Pierce SK
Vaccine; 2009 Dec; 27(52):7299-303. PubMed ID: 19712767
[TBL] [Abstract][Full Text] [Related]
2. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults.
Sagara I; Ellis RD; Dicko A; Niambele MB; Kamate B; Guindo O; Sissoko MS; Fay MP; Guindo MA; Kante O; Saye R; Miura K; Long C; Mullen GE; Pierce M; Martin LB; Rausch K; Dolo A; Diallo DA; Miller LH; Doumbo OK
Vaccine; 2009 Dec; 27(52):7292-8. PubMed ID: 19874925
[TBL] [Abstract][Full Text] [Related]
3. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
Tougan T; Aoshi T; Coban C; Katakai Y; Kai C; Yasutomi Y; Ishii KJ; Horii T
Hum Vaccin Immunother; 2013 Feb; 9(2):283-90. PubMed ID: 23291928
[TBL] [Abstract][Full Text] [Related]
4. Why haven't we made an efficacious vaccine for malaria?
Wykes MN
EMBO Rep; 2013 Aug; 14(8):661. PubMed ID: 23846309
[No Abstract] [Full Text] [Related]
5. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9.
Coban C; Igari Y; Yagi M; Reimer T; Koyama S; Aoshi T; Ohata K; Tsukui T; Takeshita F; Sakurai K; Ikegami T; Nakagawa A; Horii T; Nuñez G; Ishii KJ; Akira S
Cell Host Microbe; 2010 Jan; 7(1):50-61. PubMed ID: 20114028
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
9. Hemozoin: malaria's "built-in" adjuvant and TLR9 agonist.
Wagner H
Cell Host Microbe; 2010 Jan; 7(1):5-6. PubMed ID: 20114022
[TBL] [Abstract][Full Text] [Related]
10. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals.
Crompton PD; Mircetic M; Weiss G; Baughman A; Huang CY; Topham DJ; Treanor JJ; Sanz I; Lee FE; Durbin AP; Miura K; Narum DL; Ellis RD; Malkin E; Mullen GE; Miller LH; Martin LB; Pierce SK
J Immunol; 2009 Mar; 182(5):3318-26. PubMed ID: 19234231
[TBL] [Abstract][Full Text] [Related]
11. TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine.
Coban C; Horii T; Akira S; Ishii KJ
Expert Rev Vaccines; 2010 Jul; 9(7):775-84. PubMed ID: 20624050
[TBL] [Abstract][Full Text] [Related]
12. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Druilhe P; Spertini F; Soesoe D; Corradin G; Mejia P; Singh S; Audran R; Bouzidi A; Oeuvray C; Roussilhon C
PLoS Med; 2005 Nov; 2(11):e344. PubMed ID: 16262450
[TBL] [Abstract][Full Text] [Related]
13. B cell analysis of ethnic groups in Mali with differential susceptibility to malaria.
Portugal S; Doumtabe D; Traore B; Miller LH; Troye-Blomberg M; Doumbo OK; Dolo A; Pierce SK; Crompton PD
Malar J; 2012 May; 11():162. PubMed ID: 22577737
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium falciparum-specific IgM B cells dominate in children, expand with malaria, and produce functional IgM.
Hopp CS; Sekar P; Diouf A; Miura K; Boswell K; Skinner J; Tipton CM; Peterson ME; Chambers MJ; Andrews S; Lu J; Tan J; Li S; Doumbo S; Kayentao K; Ongoiba A; Traore B; Portugal S; Sun PD; Long C; Koup RA; Long EO; McDermott AB; Crompton PD
J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33661303
[TBL] [Abstract][Full Text] [Related]
15. Malaria vaccine based on self-assembling protein nanoparticles.
Burkhard P; Lanar DE
Expert Rev Vaccines; 2015; 14(12):1525-7. PubMed ID: 26468608
[TBL] [Abstract][Full Text] [Related]
16. Young lives lost as B cells falter: what we are learning about antibody responses in malaria.
Portugal S; Pierce SK; Crompton PD
J Immunol; 2013 Apr; 190(7):3039-46. PubMed ID: 23526829
[TBL] [Abstract][Full Text] [Related]
17. Recognition of Plasmodium falciparum mature gametocyte-infected erythrocytes by antibodies of semi-immune adults and malaria-exposed children from Gabon.
Gebru T; Ajua A; Theisen M; Esen M; Ngoa UA; Issifou S; Adegnika AA; Kremsner PG; Mordmüller B; Held J
Malar J; 2017 Apr; 16(1):176. PubMed ID: 28446190
[TBL] [Abstract][Full Text] [Related]
18. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
[TBL] [Abstract][Full Text] [Related]
19. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination.
Miura K; Zhou H; Moretz SE; Diouf A; Thera MA; Dolo A; Doumbo O; Malkin E; Diemert D; Miller LH; Mullen GE; Long CA
J Immunol; 2008 Dec; 181(12):8776-83. PubMed ID: 19050299
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
